Skip to Content


Guidance for Industry on Changes to an Approved New Drug Application or Abbreviated New Drug Application; Availability; Correction

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Notice; correction.


The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 8, 2004 (69 FR 18768). The document announced the availability of a revised guidance for industry entitled “Changes to an Approved NDA or ANDA.” The document was published with inadvertent errors. This document corrects those errors.

Start Further Info


Joyce A. Strong, Office of Policy and Planning (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7010.

End Further Info End Preamble Start Supplemental Information


In FR Doc. 04-7533, appearing on page 18768 in the Federal Register of Thursday, April 8, 2004, the following corrections are made:

1. On page 18768, in the first column, under the FOR FURTHER INFORMATION CONTACT section, the contact information is corrected to read “David J. Cummings, Center for Drug Evaluation and Research (HFD-357), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5187.”

2. On page 18768, in the third column, the second full paragraph is removed.

Start Signature

Dated: April 19, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 04-9324 Filed 4-23-04; 8:45 am]